Molecular structure of Deferoxamine mesylate, CAS Number: 138-14-7
Deferoxamine mesylate (CAS 138-14-7)
See product citations (19)
Alternate Names:
Deferoxamine mesylate is also known as DFOM.
Application:
Deferoxamine mesylate is a bacterial siderophore, an iron chelator which induces apoptosis and is used to experimentally inhibit iron-dependent prolyl hydoxylases.
CAS Number:
138-14-7
Purity:
≥94%
Molecular Weight:
656.79
Molecular Formula:
C25H48N6O8•CH4O3S
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Deferoxamine Mesylate, an iron chelator, has been found to inhibit thymidine incorporation in cell cultures which is antagonized by iron supplementation. Iron has been reported to be involved in the control of enzymatic activities that regulate DNA synthesis in cells. Deferoxamine mesylate has been found to induce apoptosis by causing chromatin condensation. Additionally, it has the ability to induce p53 and cell accumulation in the G1 phase of cell growth and increase p21 mRNA levels without any detectable protein products. Furthermore, studies suggest that Deferoxamine mesylate is capable of activating HIF-1alpha (hypoxia-inducible factor 1alpha), consequently causing transcription of numerous genes that are associated with hypoxia. Deferoxamine Mesylate is an inhibitor of Prolyl Hydroxylase.
Deferoxamine mesylate (CAS 138-14-7) References
- Inhibitory effect of deferoxamine mesylate and low iron diet on the 13762NF rat mammary adenocarcinoma. | Wang, F., et al. 1999. Anticancer Res. 19: 445-50. PMID: 10226580
- Induction of apoptosis by iron depletion in the human breast cancer MCF-7 cell line and the 13762NF rat mammary adenocarcinoma in vivo. | Jiang, XP., et al. 2002. Anticancer Res. 22: 2685-92. PMID: 12529982
- Deferoxamine enhances neovascularization and recovery of ischemic skeletal muscle in an experimental sheep model. | Chekanov, VS., et al. 2003. Ann Thorac Surg. 75: 184-9. PMID: 12537214
- Deferoxamine mesylate is toxic for retinal pigment epithelium cells in vitro, and its toxicity is mediated by p38. | Klettner, A., et al. 2010. Cutan Ocul Toxicol. 29: 122-9. PMID: 20380623
- The effects of deferoxamine mesylate on iron elimination after blood transfusion in neonatal foals. | Elfenbein, JR., et al. 2010. J Vet Intern Med. 24: 1475-82. PMID: 20958791
- Protective effects of deferoxamine mesylate preconditioning on pancreatic tissue in orthotopic liver autotransplantation in rats. | Li, Y., et al. 2011. Transplant Proc. 43: 1450-5. PMID: 21693216
- Deferoxamine mesylate enhances virulence of community-associated methicillin resistant Staphylococcus aureus. | Arifin, AJ., et al. 2014. Microbes Infect. 16: 967-72. PMID: 25251026
- Source of iron in neutrophil-mediated killing of endothelial cells. | Gannon, DE., et al. 1987. Lab Invest. 57: 37-44. PMID: 3037192
- Formulation and In-Vitro Characterization of Chitosan-Nanoparticles Loaded with the Iron Chelator Deferoxamine Mesylate (DFO). | Lazaridou, M., et al. 2020. Pharmaceutics. 12: PMID: 32156022
- The effects of deferoxamine mesylate on gallium-67 distribution in normal and abscess-bearing animals: concise communication. | Oster, ZH., et al. 1980. J Nucl Med. 21: 421-5. PMID: 7373412
- Iron deprivation-induced apoptosis in HL-60 cells. | Fukuchi, K., et al. 1994. FEBS Lett. 350: 139-42. PMID: 8062913
- Deferoxamine posttreatment reduces ischemic brain injury in neonatal rats. | Palmer, C., et al. 1994. Stroke. 25: 1039-45. PMID: 8165675
- Antiproliferative effect of desferrioxamine on vascular smooth muscle cells in vitro and in vivo. | Porreca, E., et al. 1994. Arterioscler Thromb. 14: 299-304. PMID: 8305423
- Stabilization of wild-type p53 by hypoxia-inducible factor 1alpha. | An, WG., et al. 1998. Nature. 392: 405-8. PMID: 9537326
- DNA damage induces p21 protein expression by inhibiting ubiquitination in ML-1 cells. | Fukuchi, K., et al. 1998. Biochim Biophys Acta. 1404: 405-11. PMID: 9739169
Inhibitor of:
β-defensin 37, β-defensin 38, β-defensin 39, ALAS-E, ALAS-H, BOLA2B, CD71, CYB561D2, E330017A01Rik, EG434726, FLVCR, GPx-3, Hepcidin, HIF PHD, HIF PHD3, Integrin β6, ISCA1, Mitoferrin, MMADHC, MTF-1, NARFL, NIPSNAP1, NUBP1, OGFOD2, OTTMUSG00000016694, P5CR2, PANK1, PGAM4, pHyde, Prolyl Hydroxylase, PTPψ, SFXN5, SLC39A11, SLC48A1, Sptrx-2, STEAP, URO-10, VAP-1, ZCSL3, ZNF336, and ZNF77.Activator of:
ABCB6, ALAS-E, Alphavirus, ANKZF1, BOCT, BOLA2, BRI3BP, Candida albicans, CYB5D2, cytoglobin, DnaJB14, eIF3θ, Epo, FBL5, FRRS1, GBP3, Grx5, Hbb-bh1, Hemopexin, HIF-1 alpha, HIF-3α, HNF-1α, HscB, ISCA1/1L, MAGE-A8, MGC87042, Mitoferrin 2, NOL55, OTTMUSG00000016694, p20-ARC, P4HA1, P4HA2, P5CR, PC5/6, PHD3, Purβ, SFXN1, and SKIV2L2.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Deferoxamine mesylate, 1 g | sc-203331 | 1 g | $255.00 | |||
Deferoxamine mesylate, 5 g | sc-203331A | 5 g | $1039.00 | |||
Deferoxamine mesylate, 10 g | sc-203331B | 10 g | $2866.00 | |||
Deferoxamine mesylate, 50 g | sc-203331C | 50 g | $4306.00 | |||
Deferoxamine mesylate, 100 g | sc-203331D | 100 g | $8170.00 |